1. New Oral Anticoagulants and VTE Management

2. Percentage of Patients at Risk for VTE by Country

3. Percentage of At-Risk Patients Receiving Recommended Prophylaxis

4. Recurrent VTE Is a Common Complication

5. Challenges and Limitations of VKAs

6. Currently Available Anticoagulants

7. Conventional 2-Stage Treatment of VTE

8. New Oral Anticoagulants

9. Anticoagulant Profiles

11. Comparisons of Designs of Phase III Acute VTE Trials

12. RE-COVER Ia and IIb Studies Efficacy and Safety of Dabigatran Compared to Warfarin for 6-Month Treatment of Acute Symptomatic Venous Thromboembolism

13. RE-COVER I and II Efficacy and Safety Outcomes

14. Extended VTE Treatment With Dabigatran

15. ENSTEIN-DVTa/-PEb Studies Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

16. EINSTEIN-DVT and -PE Trials: Efficacy and Safety Outcomes

17. EINSTEIN Extension Study

18. AMPLIFY Study: Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

19. AMPLIFY Trial: Efficacy and Safety Outcomes

20. AMPLIFY Extension Study

21. Hokusai-VTE Study: Comparative Investigation of Edoxaban Versus in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots

22. Hokusai-VTE Study

23. Opportunities for NOACs in VTE

24. Challenges for NOACs

25. Abbreviations

26. Abbreviations (cont)